Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome

References

• Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62–65. doi:10.1002/hon.2586
   PubMedGoogle Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28(33):4976–4984. doi:10.1200/JCO.2010.30.8791
   PubMed Web of Science ®Google Scholar
• Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy, a review. J Nephrol. 2019;32(2):189–198. doi:10.1007/s40620-018-0492-4
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889–1893. doi:10.1001/archinte.158.17.1889
   PubMedGoogle Scholar
• Chow CC, Mo KL, Chan CK, et al. Renal impairment in patients with multiple myeloma. Hong Kong Med J. 2003;9(2):78–82.
   PubMedGoogle Scholar
• Torra R, Blade J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995;91(4):854–859. doi:10.1111/j.1365-2141.1995.tb05400.x
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–1136. doi:10.1681/ASN.2010080857
   PubMed Web of Science ®Google Scholar
• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–959. doi:10.1182/blood-2012-04-403733
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423–429. doi:10.1038/leu.2012.182
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635–4641. doi:10.1200/JCO.2010.28.1238
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, San Miguel JF, Jagannath S, et al. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18(8):2145–2163. doi:10.1158/1078-0432.CCR-11-0498
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015;100(5):e207–e210. doi:10.3324/haematol.2014.118182
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Merlini G, Bridoux F, et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24(7):e293–e311. doi:10.1016/S1470-2045(23)00223-1
   PubMed Web of Science ®Google Scholar
• Klank D, Hoffmann M, Porubsky S, et al. Histological findings in kidney biopsies of patients with monoclonal gammopathy-always a surprise. Diagnostics (Basel). 2022;12(8):1912. doi:10.3390/diagnostics12081912.
   PubMedGoogle Scholar
• Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786–794. doi:10.1053/j.ajkd.2011.12.028
   PubMed Web of Science ®Google Scholar
• Lin ZS, Yu XJ, Zhang X, et al. Monoclonal immunoglobulin-associated renal lesions in patients with newly diagnosed multiple myeloma: a report from a single center. Cancer Manag Res. 2021;13:3879–3888. doi:10.2147/CMAR.S301818
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2012;8(1):43–51. doi:10.1038/nrneph.2011.168
   Web of Science ®Google Scholar
• Mene P, Stoppacciaro A, Lai S, et al. Light chain cast nephropathy in multiple myeloma: prevalence, impact and management challenges. Int J Nephrol Renovasc Dis. 2022;15:173–183. doi:10.2147/IJNRD.S280179
   PubMed Web of Science ®Google Scholar
• Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020;135(21):1833–1846. doi:10.1182/blood.2019003807
   PubMed Web of Science ®Google Scholar
• Finkel KW, Cohen EP, Shirali A, et al. Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy. Clin J Am Soc Nephrol. 2016;11(12):2273–2279. doi:10.2215/CJN.01640216
   PubMed Web of Science ®Google Scholar
• Bridoux F, Delbes S, Sirac C, et al. Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress. Presse Med. 2012;41(3 Pt 1):276–289. doi:10.1016/j.lpm.2011.11.008
   PubMed Web of Science ®Google Scholar
• Ecotiere L, Thierry A, Debiais-Delpech C, et al. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2016;31(1):64–72. doi:10.1093/ndt/gfv283
   PubMed Web of Science ®Google Scholar
• Jennette JC, Olson JL, Schwartz MM, et al. Heptinstall's pathology of the kidney2014.
   Google Scholar
• Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557. doi:10.1200/JCO.2015.65.0044
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Richardson P, Miguel S, et al. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126(7):921–922. doi:10.1182/blood-2015-05-647636
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol. 2000;65(3):175–181. doi:10.1034/j.1600-0609.2000.90221.x
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J. 2017;7(6):e571. doi:10.1038/bcj.2017.49
   PubMedGoogle Scholar
• Szabo AG, Thorsen J, Iversen KF, et al. Clinically-suspected cast nephropathy: a retrospective, national, real-world study. Am J Hematol. 2020;95(11):1352–1360. doi:10.1002/ajh.25959
   PubMed Web of Science ®Google Scholar
• Sharma R, Jain A, Jandial A, et al. Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment. Clin Lymphoma Myeloma Leuk. 2022;22(8):626–634. doi:10.1016/j.clml.2022.04.013
   PubMed Web of Science ®Google Scholar
• Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia. 2015;29(5):1195-1201. doi:10.1038/leu.2015.15
   PubMed Web of Science ®Google Scholar